After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. The stock was recently discussed on Yahoo Finance as it revealed that BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. The current market capitalization of BridgeBio Pharma Inc is $6.47B. A total of 1.41 million shares were traded on the day, compared to an average of 1.78M shares.
Insider Activity
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, BBIO has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 9 BUYs and 20 SELLs from insiders. Insiders purchased 410,932 shares during that period but sold 2,346,927.
In the most recent transaction, Valantine Hannah sold 2,915 shares of BBIO for 37.97 per share on Jan 16. After the transaction, the Director now owns 1,764 company shares. In a previous transaction on Dec 26, MCCORMICK FRANK sold 100,000 shares at 42.06 per share. BBIO shares that Director owns now total 627,689.
Among the insiders who sold shares, Scott Randal W. disposed of 2,000 shares on Dec 18 at a per-share price of $40.00. This resulted in the Director holding 9,000 shares of BBIO after the transaction. In another insider transaction, Valantine Hannah sold 2,915 shares at $36.12 per share on Dec 15. Company shares held by the Director now total 1,764.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for BBIO in the last 3 months, the mean price target is $47.23 with high estimates of $60.00 and low estimates of $33.00. In terms of 52-week highs and lows, BBIO has a high of $44.32 and a low of $10.57.
As of this writing, BBIO has an earnings estimate of -$0.91 per share for the current quarter. EPS was calculated based on a consensus of 11 estimates, with a high estimate of -$0.72 per share and a lower estimate of -$1.16. The company reported an EPS of -$0.98 in the last quarter, which was -18.10% lower than expectations of -$0.83.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. BBIO’s latest balance sheet shows that the firm has $836.66M in Cash & Short Term Investments as of fiscal 2021. There were $1.73B in debt and $135.07M in liabilities at the time. Its Book Value Per Share was -$6.93, while its Total Shareholder’s Equity was -$865.58M.
Analysts Opinion
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BBIO is Buy with a score of 4.67.
